Release Date: July 31, 2025
Expiration Date: July 31, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in atopic dermatitis (AD). Janus kinase (JAK) inhibitors have emerged as an effective option for patients with moderate to severe AD, particularly those who have not responded adequately to conventional systemic therapies. In this educational program, these experts review the safety data from recent clinical trials of JAK inhibitors in AD management.
This educational activity is an archive of the live symposium held on June 6, 2025.
Target Audience
This educational activity is designed for dermatologists, allergists, immunologists, pediatricians, primary care physicians, nurse practitioners, physician assistants, and other health care professionals involved in diagnosing and treating patients with AD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate emerging safety data and risk profiles of JAK inhibitors, including potential adverse events, long-term safety considerations, and patient-specific risk factors.
- Apply patient-centered strategies to guide the safe initiation and monitoring of JAK inhibitors in AD management.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here